How close are we to ending Alzheimer's?

The Wall Street Journal reporter, who is the first US journalist charged with spying in Russia since the Cold War, has now been imprisoned for a year. His detention has been repeatedly extended and he is yet to face trial. His family, colleagues and the US government vehemently d ...  Show more

Over the past year thousands of journalists have lost their jobs as mass media news organisations struggle to make ends meet. Ad revenue is down, many publishers are struggling to gain subscribers, and social media has resulted in plummeting traffic to homepages. More than a thir ...  Show more

<div><span style= "font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;"> Amanda Grant Smith is a geriatric psychiatrist with decades of experience treating patients with dementia and Alzheimer's ...  Show more

A new drug for Alzheimer's disease, called lecanemab, got a lot of attention earlier this year for getting fast-tracked approval based on a clinical trial that included nearly 1,800 people. It was the most diverse trial for an Alzheimer's treatment to date, but still not enough t ...  Show more

Alzheimer's disease is a devastating neurodegenerative condition that affects the entire family. As psychiatrists and psychologists, we often support these patients and their families throughout this entire disease process. With the recent and controversial FDA approval of aducan ...  Show more

After decades without progress, this June a new treatment was approved by the US Food and Drugs Administration - Biogen's Aduhelm. Ivana Davidovic looks into why this process has been so controversial that is now under investigation by a federal watchdog.Aaron Kesselheim, a Harva ...  Show more